Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)

Grothey, 2013, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 381, 303, 10.1016/S0140-6736(12)61900-X Li, 2015, Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 16, 619, 10.1016/S1470-2045(15)70156-7 Tabernero, 2015, Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial, Lancet Oncol, 16, 937, 10.1016/S1470-2045(15)00138-2 Heinemann, 2015, Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC), Eur J Cancer, 51, 1927, 10.1016/j.ejca.2015.06.116 Chun, 2009, Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases, JAMA, 302, 2338, 10.1001/jama.2009.1755 Ricotta, 2013, Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab, Clin Colorectal Cancer, 12, 45, 10.1016/j.clcc.2012.07.001 Ricotta, 2013, Regorafenib for metastatic colorectal cancer, Lancet, 381, 1537, 10.1016/S0140-6736(13)60976-9 Ricotta, 2015, E17Cavitation of lung metastases induced by regorafenib is associated with radiological response in metastatic colorectal cancer: data from the phase III correct study, Ann Oncol, 26, vi41.2 Ricotta, 2015, 2015 Cavitation of lung metastases induced by regorafenib in patients with colorectal carcinoma: Data from the phase III CORRECT study, Eur J Cancer, 51, S333, 10.1016/S0959-8049(16)30939-X Stone, 1985, Additive splines in statistics, 45 Harrell, 2011, Regression Modeling Strategies Breiman, 1984 Sandler, 2009, Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab, J Clin Oncol, 27, 1405, 10.1200/JCO.2008.16.2412 Reck, 2012, Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts, Ann Oncol, 23, 1111, 10.1093/annonc/mdr463 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Choi, 2007, Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria, J Clin Oncol, 25, 1753, 10.1200/JCO.2006.07.3049 Desar, 2009, Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy, Cancer Treat Rev, 35, 309, 10.1016/j.ctrv.2008.12.001 Jaffe, 2006, Measures of response: RECIST, WHO, and new alternatives, J Clin Oncol, 24, 3245, 10.1200/JCO.2006.06.5599 Chaudhuri, 1970, Cavitary pulmonary metastases, Thorax, 25, 375, 10.1136/thx.25.3.375 Nishino, 2012, Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab, Cancer Imaging, 12, 225, 10.1102/1470-7330.2012.0027 Marom, 2008, Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer, J Thorac Oncol, 3, 351, 10.1097/JTO.0b013e318168c7e9 Phernambucq, 2012, Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes, J Thorac Oncol, 7, 1271, 10.1097/JTO.0b013e3182582912 Crabb, 2009, Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer, J Clin Oncol, 27, 404, 10.1200/JCO.2008.16.2545 Lee, 2011, New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy, Lung Cancer, 73, 63, 10.1016/j.lungcan.2010.10.019 Lim, 2015, Clinical implication of anti-angiogenic effect of regorafenib in metastatic colorectal cancer, PLoS One, 10, e0145004, 10.1371/journal.pone.0145004 Boonsirikamchai, 2011, CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab, AJR Am J Roentgenol, 197, W1060, 10.2214/AJR.11.6459 Cyran, 2013, Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation, PLoS One, 8, e76009, 10.1371/journal.pone.0076009 Wilhelm, 2011, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity, Int J Cancer, 129, 245, 10.1002/ijc.25864 Strumberg, 2012, Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study, Br J Cancer, 106, 1722, 10.1038/bjc.2012.153 Shinagare, 2014, Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib, Eur J Cancer, 50, 981, 10.1016/j.ejca.2013.11.037